Q-omics provides the consensus-scored TTTY5 profile across patient tissues and cancer cell-line models. TTTY5 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TTTY5 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, TTTY5 RNA expression shows 5,453 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCEC, LUSC, and ESCA as cancer lineages where TTTY5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTTY5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTTY5 survival associations across molecular data types. TTTY5 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTTY5 RNA expression–survival associations across cancer types. High TTTY5 expression shows unfavorable associations in UCEC, ACC, LIHC, HNSC, STAD and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TTTY5 RNA expression.
This table summarizes TTTY5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TTTY5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTTY5 shows lower tumor expression in LUSC. The LUSC box plot shows higher TTTY5 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p = .002).
This table shows molecular features associated with TTTY5 in patient tissues and cancer cell lines. In patient samples, TTTY5 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
